Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform

Author(s): Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P,et al.


The focus of nanoparticle design over the years has evolved toward more complex nanoscopic core–shell architecture using a single delivery system to combine multiple functionalities within nanoparticles. Core–shell-type lipid–polymer hybrid nanoparticles (CSLPHNs), which combine the mechanical advantages of biodegradable polymeric nanoparticles and biomimetic advantages of liposomes, have emerged as a robust and promising delivery platform. In CSLPHNs, a biodegradable polymeric core is surrounded by a shell composed of layer(s) of phospholipids. The hybrid architecture can provide advantages such as controllable particle size, surface functionality, high drug loading, entrapment of multiple therapeutic agents, tunable drug release profile, and good serum stability. This review focuses on current research trends on CSLPHNs including classification, advantages, methods of preparation, physicochemical characteristics, surface modifications, and immunocompatibility. Additionally, the review deals with applications for cancer chemotherapy, vaccines, and gene therapeutics.

Similar Articles

Hallmarks of cancer: the next generation

Author(s): Hanahan D, Weinberg RA

Side effects of chemotherapy

Author(s): Burstein HJ

Therapeutic nanoparticles for drug delivery in cancer

Author(s): Cho K, Wang X, Nie S, Chen ZG, Shin DM

Synthesis of biocompatible Au–ZnTe core–shell nanoparticles

Author(s): Dunpall R, Lewis EA, Haigh SJ, O'Brien P, Revaprasadu N

Nanomaterial cytotoxicity is composition, size, and cell type dependent

Author(s): Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L

Nanoparticle and targeted systems for cancer therapy

Author(s): Brannon-Peppas L, Blanchette JO